文献速递妇科

铂敏感复发性卵巢癌患者二次肿瘤细胞减灭术的结局

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
PubMed 文献 · Am J Obstet Gynecol · 2019-06-14

这项回顾性队列研究纳入6个国家癌症研究所指定中心的626例铂敏感复发性卵巢癌患者,比较二次手术与化疗的总生存。倾向评分匹配后,手术组中位总生存54个月,化疗组33个月,但未测量的混杂因素可能解释该差异。

要点

  • 626例中146例(23%)接受二次手术,480例(77%)接受化疗。
  • 匹配后手术组中位总生存54个月 vs 化疗组33个月(P<0.001)。
  • 手术组102例(70%)达到满意二次减灭,两组并发症率无显著差异。

核心结论

  • 接受二次手术的铂敏感复发性卵巢癌患者具有有利的手术特征,二次手术后可能达到最小残留病灶。
  • 这些患者的中位总生存优于接受化疗的患者,但未测量的混杂因素可能解释这一观察到的差异。

研究设计与样本

  • 回顾性队列研究,纳入2004年1月1日至2011年12月31日期间在6个国家癌症研究所指定癌症中心诊断为铂敏感复发性卵巢癌的女性。
  • 共626例女性,146例(23%)接受二次手术,480例(77%)接受化疗;采用倾向评分匹配比较相似女性。
  • 主要结局为总生存;额外分析检验复发时未观察混杂因素的普遍程度如何影响这些发现。

主要发现

  • 在调整分析中,接受二次手术的患者较接受化疗者更年轻(P=0.001)、诊断时分期更早(P=0.002)、无病间期更长(P<0.001)。
  • 在倾向评分匹配组(n=244例患者)中,接受二次手术的患者中位总生存为54个月,接受化疗者为33个月(P<0.001)。
  • 在接受二次手术的患者中,102例(70%)达到满意二次减灭;两组并发症率无显著差异。
  • 在敏感性分析中,二次手术相关的生存优势可由接受化疗而非二次手术的患者中更常见的多灶性复发(若常见4.3倍)、腹水(若常见2.7倍)或癌病(若常见2.1倍)来解释。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未测量的混杂因素可能解释观察到的二次手术与化疗之间的生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most women with advanced epithelial ovarian cancer develop recurrent disease, despite maximal surgical cytoreduction and adjuvant platinum-based chemotherapy. In observational studies, secondary cytoreductive surgery has been associated with improved survival; however its use is controversial, because there are concerns that the improved outcomes may reflect selection bias rather than the superiority of secondary surgery. OBJECTIVE: To compare the overall survival of women with platinum-sensitive recurrent ovarian cancer treated at National Cancer Institute-designated cancer centers who receive secondary surgery vs chemotherapy. STUDY DESIGN: This retrospective cohort study included women from 6 National Cancer Institute-designated cancer centers diagnosed with platinum-sensitive recurrent ovarian cancer between January 1, 2004, and December 31, 2011. The primary outcome was overall survival. Propensity score matching was used to compare similar women who received secondary surgery vs chemotherapy. Additional analyses examined how these findings may be influenced by the prevalence of unobserved confounders at the time of recurrence. RESULTS: Among 626 women, 146 (23%) received secondary surgery and 480 (77%) received chemotherapy. In adjusted analyses, patients who received secondary surgery were younger (P = 0.001), had earlier-stage disease at diagnosis (P = 0.002), and had longer disease-free intervals (P < 0.001) compared with those receiving chemotherapy. In the propensity score-matched groups (n = 244 patients), the median overall survival was 54 months in patients who received secondary surgery and 33 months in those treated with chemotherapy (P < 0.001). Among patients who received secondary surgery, 102 (70%) achieved optimal secondary cytoreduction. There were no significant differences in complication rates between the 2 groups. In sensitivity analyses, the survival advantage associated with secondary surgery could be explained by the presence of more multifocal recurrences (if 4.3 times more common), ascites (if 2.7 times more common), or carcinomatosis (if 2.1 times more common) among patients who received chemotherapy instead of secondary surgery. CONCLUSION: Patients with platinum-sensitive recurrent ovarian cancer who received secondary surgery had favorable surgical characteristics and were likely to have minimal residual disease following secondary surgery. These patients had a superior median overall survival compared with patients who received chemotherapy, although unmeasured confounders may explain this observed difference.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gockley A, Melamed A, Cronin A, et al. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019. PMID: 31207237. doi:10.1016/j.ajog.2019.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。